How MedTech companies can build integrated clinical evidence strategies for global regulatory success

Clinical evidence generated in one market can often support regulatory submissions in others, but only if it has been designed with international expectations in mind. Regulators expect robust evidence that demonstrates safety and performance, and each jurisdiction applies its own regulatory framework and assesses data generated in another market against its own clinical practice, standard of care, and regulatory precedents.

To better understand how medical device manufacturers can maximize the global value of their clinical evidence, MedTech World spoke with Mercè Guerra, Associate Director of Regulatory Affairs at Alira Health. In this interview, she outlines the key factors regulators consider when it comes to device approval, the evidence most likely to be accepted across jurisdictions, and the common regulatory pitfalls that can delay international expansion.

The right moment to start building clinical evidence-generation plan for future markets

According to Guerra, for MedTech companies with international commercialization ambitions, clinical evidence planning should begin as early as product development allows.

“Proactive planning can significantly reduce future development timelines, costs, and regulatory risk. The objective is not to implement every future regulatory and clinical requirement immediately, but to understand those requirements early enough to make informed development decisions.”

Understanding country-specific regulatory requirements early helps manufacturers avoid generating evidence that is difficult or impossible to leverage in later submissions. Early planning also provides greater flexibility to adapt overall clinical development.

Practical examples of evidence planning include:

• identifying country-specific differences early so they can be addressed through future studies or bridging strategies, thus avoiding delaying market expansion.
• considering additional secondary endpoints that may be valuable for future submissions.
• developing a real-world evidence strategy capable of generating complementary evidence for additional markets.

How to design integrated global evidence strategies for approval in multiple markets

Successful global commercialization strategies begin with a clear regulatory strategy that then influences the clinical development plan for the product. Guerra recommends that manufacturers first define the priority target markets and perform a comprehensive assessment of regulatory requirements across those jurisdictions, before they define the specificities and finalize the clinical development plan.

“A clear and early picture of regional requirements allows manufacturers to proactively address evidence gaps rather than discover them during preparation for future submissions.”

Manufacturers should then identify common evidence requirements that can support multiple submissions simultaneously and highlight regional differences early. It is important to determine whether these differences should be addressed within the initial clinical program or through complementary approaches such as real-world evidence, bridging studies, or post-market clinical follow-up.

Finally, manufacturers should maintain regular dialogue with regulatory authorities throughout development and establish clear regional priorities if commercial or development priorities change over time.

“Rather than building separate clinical strategies for every market, manufacturers should design a core integrated global evidence strategy that considers shared regulatory expectations while maintaining sufficient flexibility to address local requirements where necessary.”

According to Guerra, common pitfalls in global regulatory strategy design include:

• failing to review country-specific regulatory guidance and requirements before clinical program design.
• insufficient assessment of local clinical practice and standard of care.
• limited understanding of competing technologies and existing regulatory precedents within the target market.
• underestimating differences in patient populations, including race, ethnicity, disease characteristics, and healthcare access.
• engaging regulators only after studies in other regions have been completed.
• waiting until initial market approval before evidence requirements evaluation for future markets.

Determinants of evidence acceptance abroad

Guerra suggests common determinants of success when MedTech companies leverage data generated in home country to support approval in the EU, US, or in other regions, include compliance with local regulatory expectations, population representativeness, selection of standard of care, and alignment with previous regulatory precedents.

“Manufacturers should evaluate previous regulatory decisions for comparable devices and indications. Understanding what evidence has previously been accepted by local authorities helps ensure that future clinical strategies align with regulatory precedent.”

Although every submission is evaluated individually, some evidence packages are consistently more transferable across jurisdictions than others.

This type of evidence can include:

• studies designed according to internationally recognized standards with guidelines aligned with local regulations.
• clinical strategies that have been designed and supported by early interactions with regulatory authorities, allowing study design elements to be discussed and aligned before trial execution.
• data generated in multi-regional studies with clinical sites in several countries that support extrapolation across countries.
• clinical strategies with relevant endpoints that are clinically meaningful and aligned with what local regulators, clinical guidelines, physicians, and healthcare systems consider important.

At the same time, regulators can request bridging data or additional justification in situations when:

• study designs do not reflect local regulatory expectations or established regulatory precedents.
• applicability of the observed benefit-risk profile to the target population has not been adequately demonstrated.
• clinical evidence is based on treatment pathways or standards of care that differ substantially from those used locally.
• comparators, endpoints, follow-up periods, or statistical assumptions are insufficiently justified for the target jurisdiction.

In these cases, Guerra recommends that MedTech companies conduct a formal gap assessment when regional differences exist; providing a well-supported scientific justification can substantially improve the likelihood of regulatory acceptance.

Final takeaways

Successful global clinical evidence strategies are rarely developed one country at a time. Instead, they are built with international expansion in mind from the earliest stages of product development.

With a clear outline of where regulatory expectations overlap and where they differ, manufacturers can generate evidence that supports multiple markets, minimizes duplication, reduces development costs, and accelerates patient access worldwide.

“Ultimately, global expansion depends less on the creation of separate evidence packages for every jurisdiction, and more on the design of an integrated and flexible clinical strategy that balances global efficiency with local regulatory expectations.”